1.6 x 10'1-') as was median nadir platelet count (175 vs 157 x 1091-'). There was no evidence of significant cardiac toxicity. The median plasma quinidine level achieved was 5.6 lmoll-I (range 2.1-22.1), which is within the range of concentrations which is effective in vitro at reversing experimental anthracycline resistance. A randomised controlled study is proposed to assess the impact of this potential modulation on the efficacy of epirubicin in advanced breast cancer.
Adriamycin is the most effective single agent in the treatment of advanced breast cancer (Carter, 1976) . Tumour cell resistance to adriamycin and other anthracyclines limits the effectiveness of these drugs in breast cancer. One mechanism of resistance demonstrated in vitro depends on increased expression of the multidrug resistant (MDR) gene which leads to increased production of a specific membrane glycoprotein, P-glycoprotein (Kaye, 1988 ). P-glycoprotein confers resistance by functioning as an energy-dependent efflux pump at the cell membrane, reducing intracellular drug concentration and hence reducing cytotoxicity. It has been shown experimentally that non-cytotoxic drugs such as verapamil and quinidine can reverse this process by binding to P-glycoprotein (Tsuruo et al., 1984; Yusa & Tsuruo, 1989) . In the MDR resistant breast cancer cell line MCF-7, quinidine has been found to be an effective modulator of resistance, increasing by 8-fold the sensitivity of this line to adriamycin (Brown et al., 1989) (Table I ).
Haematological toxicity The median nadir WBC with the first course of epirubicin, without quinidine, was 2.3 x I0 1-' (range 1.1-4.5) while that for courses 2-4, with quinidine 250mg b.d., was 1.5 x 10 1-' (range 1.0-5.9). The equivalent values for platelets with and without quinidine were 175 x 109 1`(range and 158 x 109 1-' (range 37-565). The median nadirs for subsequent courses with quinidine were similar and did not show evidence of cumulative toxicity (Table II) .
There was no evidence of increased nausea and vomiting or mucositis compared with epirubicin 100 mg m-2 alone. Hair loss occurred in all patients.
Cardiac toxicity Electrocardiography, 24 h monitoring and echocardiography did not reveal any evidence of cardiac toxicity. Q-T intervals were analysed on ECG recordings and did not show any significant prolongation with the quinidine doses used. At the end of a full course of epirubicin, repeat echocardiography showed no evidence of significant impairment of LV function (four patients).
Quinidine levels
The median plasma concentrations of quinidine in patients are shown in Table III. In the 250 mg b.d. group the median level was 5.6 ftmol I'. This is in the range active in vitro ). The median level in patients taking 500 mg b.d. of quinidine was 7.4 jsmol 1'.
Discussion
Drug resistance remains a major problem in the management of advanced breast cancer by chemotherapy. The response rate to the most active single agent, adriamycin is limited to 40-50%, and it is possible that one mechanism underlying this is the so-called multidrug resistance phenomenon. This study aimed to investigate if it were feasible to combine the response modulator, quinidine, active in the laboratory, with epirubicin, an anthracycline recently extensively studied in this centre. We also examined whether levels of quinidine known to be active in vitro could be achieved in patients, and whether the two drugs could be combined without enhancement of epirubicin toxicity.
The dose of quinidine of 1 g b.d. was selected as this dose has been found to be well tolerated by patients receiving the drug for reasons of cardiac dysrhythmia. Our three patients who received quinidine at this dose developed side-effects and, even at a dose of 500 mg b.d., three of eight patients developed problems, although one of these, who complained of nausea, subsequently completed the full eight cycles without problem when the dose of quinidine was reduced to 250 mg b.d.
Twenty patients were then entered at a quinidine dose of 250 mg b.d. Two of these were discontinued from their quinidine because of symptoms attributed to the drug. Interestingly, one developed symptoms of cinchonism with a plasma level of drug of only 3.4 j.mol; this effect generally occurs only with high drug levels. Three further patients did not complete all planned therapy because of toxicity associated with epirubicin. One of these stopped after one course because of mucositis, a recognised problem with epirubicin alone, and in this case occurring before any quinidine therapy. The problems in the other two patients were of nausea and vomiting and myelosuppression. These again are toxicities associated with epirubicin and were comparable with our experience using this drug alone at a dose of 100 mg m-2 (Habeshaw, personal communication). Myelosuppression was not a significant problem in this study and nadir data did not show evidence of enhancement of bone marrow toxicity by the response modulator. Only one patient in the 250 mg group required dose reduction because of myelosuppression.
In view of the effects of quinidine on heart rhythm and the known dose-dependent cardiotoxicity of anthracyclines, careful attention was paid to heart rhythm and function. No evidence of cardiac toxicity was found in any patient in the study. The median quinidine level in patients treated for 4 days at a dose of 250 mg in slow release form was 5.6 gAmol 1-'. This is clearly in the range active in the laboratory . Higher doses of quinidine did, as might be expected, produce higher, but not necessarily more useful, levels.
In summary, treatment of patients with advanced breast cancer with a combination of quinidine and epirubicin appears feasible. The combination does not appear to produce more toxicity than epirubicin alone, and at a dose of 250 mg b.d. quinidine levels equivalent to those active in vitro are achievable in patients.
The question remains as to whether an improvement in response rate and survival can be achieved in the clinic, by the use of quinidine to overcome anthracycline resistance. In view of our data on MDR expression in samples from previously untreated patients, we have chosen to address this question in a randomised, prospective, placebo-controlled trial, using epirubicin as initial chemotherapy for patients with advanced disease.
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